Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 90 people, planned
- Started
- 8 Feb 2024
- Expected to end
- May 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Psilocybin
- Record updated
- 17 July 2026
Who can take part
- Age
- 21 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Age 21-70 years
- Have given written informed consent
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for OUD
- No antidepressant medications for approximately 5 half-lives prior to enrollment
- Willing to undergo buprenorphine induction, has undergone buprenorphine induction in the past 3 weeks, or are in buprenorphine treatment with ongoing use of other opioids (evidenced by positive urine toxicology for buprenorphine and another opioid at time of screen)
- Reports previous buprenorphine maintenance
- Urine toxicology positive for an opioid
- Has access to stable housing
- Can read, write, and speak English fluently
- Be judged by study team clinicians to be at low risk for suicidality
- Have limited recent use of classic psychedelics (no use in the past year)
- Expresses a desire for sustained recovery from disordered opioid use
Who cannot take part
- Currently taking on a daily basis any medications (including herbal substances and supplements) with a central nervous system effect on serotonin, including serotonin-reuptake inhibitors and monoamine oxidase (MAO) inhibitors
- For individuals who have intermittent or as needed (PRN) use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose
- Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UDP-glucuronosyltransferase (UGT)1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag
- Currently taking methadone or naltrexone
- Currently on longstanding buprenorphine maintenance (3+ weeks post-induction)
- Reports of significant adverse events (severe withdrawal, medical complications, hospitalization) during previous buprenorphine induction(s)
- Unable or unwilling to discontinue acid-reducing agents or major metabolizing enzyme inhibitors for 5-half lives prior to the experimental dosing session
- Epilepsy
- Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
- Have a seizure disorder, multiple sclerosis, history of significant head trauma, central nervous system (CNS) tumor, movement disorders or any neurodegenerative condition
- Morbidly obese (>100 lbs above ideal body weight, or Body Mass Index (BMI) >=40, or BMI >=35 with high blood pressure or diabetes)
- Allergic to buprenorphine
- Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder or Major Depression with psychotic features
- Have a first or second degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or bipolar I or II disorder
- Cardiovascular conditions: hypertension with resting blood pressure systolic >139 or diastolic >89, angina, heart rate > 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc > 450), transient ischemic attack (TIA) in the last 6 months, stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy
- For blood samples, the following lab values will be exclusionary: transaminases greater than x2 the upper limit of normal lab reference range, hemoglobin less than 11 g/d, and creatinine clearance < 40 ml/min using the Cockraft and Gault equation; Psychiatric Exclusion Criteria:
- General medical exclusion criteria:
- Women who are pregnant, nursing, or not practicing an effective means of birth control
- Naïve to buprenorphine
- Body weight < 45 kg
- Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
This trial is currently available in United States.
- Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, United StatesContact: Sandeep Nayak, MDTaking people
About the trial
What the trial wants to find out
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid use disorder (OUD). The participants will have previously undergone buprenorphine induction before. Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with outpatient buprenorphine maintenance, quality of life, and mood.
The 2 groups in the trial
- High-dose psilocybin + buprenorphineTreatment being tested
High-dose psilocybin (30 mg) session following standard-of-care outpatient buprenorphine induction
Treatment: Psilocybin
- Very low-dose psilocybin + buprenorphineExisting treatment, for comparison
Very low dose psilocybin session (1 mg) following standard-of-care outpatient buprenorphine induction
Treatment: Psilocybin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
- Criteria questions
- Built from NCT06067737, who can take part
- Record updated
- 17 July 2026